会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 31. 发明申请
    • Devices and methods for generating gunshot alerts
    • 用于生成枪声警报的设备和方法
    • US20150194045A1
    • 2015-07-09
    • US13589887
    • 2012-08-20
    • David A. EdwardsNarciso Macia
    • David A. EdwardsNarciso Macia
    • G08B25/10
    • G08B13/1672G01H3/00
    • Devices and methods for generating gunshot alerts are provided. In some embodiments, devices for generating a gunshot alert are provided, the devices comprising: a microphone having an output; an amplifier having an input coupled to the output of the microphone and an output; a band-pass filter having an input coupled to the output of the amplifier and an output; an analog to digital converter having an input coupled to the output of the band-pass filter and an output; a microcontroller having an input coupled to the output of the analog to digital converter and an output; and a notification device having an input coupled to the output of the microcontroller.
    • 提供了产生枪声警报的设备和方法。 在一些实施例中,提供了用于产生枪声警报的装置,所述装置包括:具有输出的麦克风; 具有耦合到所述麦克风的输出的输入和输出的放大器; 带通滤波器,具有耦合到放大器的输出端的输入端和输出端; 具有耦合到带通滤波器的输出的输入和输出的模数转换器; 微控制器,具有耦合到模数转换器的输出的输入端和输出端; 以及具有耦合到微控制器的输出的输入的通知装置。
    • 37. 发明申请
    • FORMULATIONS LIMITING SPREAD OF PULMONARY INFECTIONS
    • 限制肺部感染蔓延的制剂
    • US20090208581A1
    • 2009-08-20
    • US12351328
    • 2009-01-09
    • David A. EdwardsHoward A. Stone
    • David A. EdwardsHoward A. Stone
    • A61K9/14C08B37/00C07K14/00A61K31/74A61K38/16A61K31/715C08B37/02C08G65/34C07K14/76A61K31/721A61K31/765A61K38/38A61P31/12A01K29/00A61D7/00
    • A61K9/0075A61K9/0078A61K31/355A61K31/685A61K31/715
    • Formulations have been developed for pulmonary delivery to treat or reduce the infectivity of diseases such as vital infections, especially tuberculosis, SARS, influenza and respiratory synticial virus in humans and hoof and mouth disease in animals. Formulations for pulmonary administration include a material that significantly alters physical properties such as surface tension and surface elasticity of lung mucus lining fluid, which may be a surfactant and, optionally, a carrier. The formulation may be administered as a powder where the particles consist basically of the material altering surface tension. The carrier may be a solution, such as an alcohol, although an aqueous solution may be utilized, or a material mixed with the material altering surface tension to form particles. These may include proteins such as albumin or polysaccharides such as dextran, which also has surface active properties, or polymers such as polyethylene oxide (PEO) or biodegradable synthetic polymers which can be used to encapsulate or deliver the materials to be delivered. Drugs, especially antivirals or antibiotics, may optionally be included with the formulation. These may be administered with or incorporated into the formulation.
    • 已经开发了用于肺部输送以治疗或减少诸如人体中的重要感染,特别是结核病,SARS,流感和呼吸道合成病毒以及动物蹄和口蹄疫的疾病的感染性的制剂。 用于肺部给药的制剂包括显着改变诸如表面活性剂和任选的载体的肺粘液衬里液体的表面张力和表面弹性的物理性质的材料。 制剂可以粉末施用,其中颗粒基本上由改变表面张力的材料组成。 载体可以是溶液,例如醇,尽管可以使用水溶液,或与材料混合的材料改变表面张力以形成颗粒。 这些可以包括诸如白蛋白或多糖的蛋白质,例如还具有表面活性的葡聚糖,或聚合物如聚环氧乙烷(PEO)或可生物降解的合成聚合物,其可用于封装或递送待递送材料。 药物,特别是抗病毒剂或抗生素,可以任选地包括在制剂中。 这些可以与制剂一起施用或掺入制剂中。
    • 38. 发明申请
    • Particles for Treatment of Pulmonary Infection
    • 用于治疗肺部感染的颗粒
    • US20080213373A1
    • 2008-09-04
    • US11720595
    • 2005-10-19
    • David A. EdwardsJennifer FiegelJean Sung
    • David A. EdwardsJennifer FiegelJean Sung
    • A61K9/14
    • A61K9/0075A61K9/1617A61K9/1694Y10S514/924
    • Formulations have been developed to treat or reduce the spread of respiratory infections, especially chronic or drug resistant infections, particularly tuberculosis (TB), severe acute respiratory syndrome (SARS), meningococcal meningitis, Respiratory syncytial virus (RSV), influenza, and small pox. Formulations include a drug or vaccine in the form of a microparticle, nanoparticle, or aggregate of nanoparticles, and, optionally, a carrier, which can be delivered by inhalation. Giving the drugs via an inhaler sidesteps the problems associated with oral or injectable drugs by bypassing the stomach and liver, and delivering the medication directly into the lungs. In one embodiment, the particle containing the agent is a large porous aerosol particle (LPPs). In another embodiment, the particles are nanoparticles, which can be administered as porous nanoparticle aggregates with micron diameters that disperse into nanoparticles following administration. Optionally, the nanoparticles are coated, such as with a surfactant or protein coating. The formulation may be administered as a powder or administered as a solution or via an enteral or non-pulmonary parenteral route of administration. The formulation is preferably administered as a pulmonary formulation. In the preferred embodiment for treatment of TB, the vaccine is a BCG vaccine that is stable at room temperature, or is an antibiotic effective against TB, such as capreomycin or PA-824, loaded at a very high percentage into the microparticles or nanoparticles. In one embodiment, a patient is treated with formulations delivering both antibiotic and vaccine.
    • 已经开发了治疗或减少呼吸道感染传播的制剂,特别是慢性或耐药性感染,特别是结核病(TB),严重急性呼吸综合征(SARS),脑膜炎球菌性脑膜炎,呼吸道合胞病毒(RSV),流感和小痘 。 制剂包括纳米颗粒的微粒,纳米颗粒或骨料形式的药物或疫苗,以及任选的可以通过吸入递送的载体。 通过吸入器给药可以通过绕过胃和肝来避开与口服或可注射药物相关的问题,并将药物直接送入肺部。 在一个实施方案中,含有该试剂的颗粒是大的多孔气溶胶颗粒(LPPs)。 在另一个实施方案中,颗粒是纳米颗粒,其可以作为具有微米直径的多孔纳米颗粒聚集体施用,其在施用后分散到纳米颗粒中。 任选地,包覆纳米颗粒,例如用表面活性剂或蛋白质涂层。 制剂可以粉末形式施用或作为溶液给药或通过肠内或非肺部非肠道途径给药。 制剂优选作为肺制剂施用。 在用于治疗结核病的优选实施方案中,疫苗是在室温下稳定的BCG疫苗,或者是针对TB有效的抗生素,例如卷曲霉素或PA-824,其以非常高的百分比加载到微粒或纳米颗粒中。 在一个实施方案中,用递送抗生素和疫苗的制剂治疗患者。